Zacks Investment Research downgraded shares of Aldeyra Therapeutics Inc. (NASDAQ:ALDX) from a buy rating to a hold rating in a research note issued to investors on Monday morning.
According to Zacks, “Aldeyra Therapeutics, Inc. is a biotechnology company. The company’s products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. “
Other research analysts have also recently issued reports about the company. HC Wainwright reaffirmed a buy rating on shares of Aldeyra Therapeutics in a research report on Friday, November 18th. Cowen and Company reaffirmed a buy rating on shares of Aldeyra Therapeutics in a research report on Tuesday, November 15th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Aldeyra Therapeutics has a consensus rating of Buy and an average price target of $14.30.
Shares of Aldeyra Therapeutics (NASDAQ:ALDX) opened at 5.95 on Monday. The firm’s market cap is $37.16 million. The firm has a 50-day moving average price of $6.36 and a 200-day moving average price of $6.04. Aldeyra Therapeutics has a 12-month low of $3.39 and a 12-month high of $8.19.
Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Monday, November 14th. The biotechnology company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.01. Equities research analysts anticipate that Aldeyra Therapeutics will post ($1.76) EPS for the current year.
A number of hedge funds have recently added to or reduced their stakes in ALDX. AWM Investment Company Inc. bought a new stake in Aldeyra Therapeutics during the second quarter valued at about $5,222,000. Perceptive Advisors LLC raised its stake in Aldeyra Therapeutics by 56.4% in the second quarter. Perceptive Advisors LLC now owns 1,940,458 shares of the biotechnology company’s stock valued at $11,041,000 after buying an additional 700,000 shares during the last quarter. FMR LLC raised its stake in Aldeyra Therapeutics by 25.0% in the second quarter. FMR LLC now owns 1,797,811 shares of the biotechnology company’s stock valued at $10,230,000 after buying an additional 360,000 shares during the last quarter. Boxer Capital LLC raised its stake in Aldeyra Therapeutics by 361.2% in the second quarter. Boxer Capital LLC now owns 291,230 shares of the biotechnology company’s stock valued at $1,657,000 after buying an additional 228,084 shares during the last quarter. Finally, Baker BROS. Advisors LP bought a new stake in Aldeyra Therapeutics during the third quarter valued at about $1,110,000. Institutional investors and hedge funds own 50.82% of the company’s stock.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.